Table 3 |
||||||||||
|
Effects of zafirlukast in subjects maintained on ics |
||||||||||
| ICS-treated + Placebo Change from baseline |
ICS-treated + Zafirlukast Change from baseline |
|||||||||
|
|
||||||||||
| Baseline (N = 8) |
Weeks 0–5 (N = 8) |
Weeks 6–10 (N = 8) |
Week 11–12 (N = 8) |
*W/D (N = 8) |
Baseline (N = 15) |
Weeks 0–5 (N = 15) |
Weeks 6–10 (N = 13) |
Week 11–12 (N = 13) |
*W/D (N = 11) |
|
|
|
||||||||||
| PEFR a.m., L/min |
353 (± 32.3) |
+13.9 (± 6.1) |
+21.1 (± 9.6) |
+17.5 (± 12.2) |
+10.4 (± 6.6) |
389 (± 21.2) |
+15.7 (± 5.0) |
+16.7 (± 6.1) |
+2.7 (± 15.2) |
-7.4 (± 6.3) |
| PEFR p.m., L/min |
373 (± 32.8) |
+9.4 (± 10.0) |
+6.4 (± 15.0) |
+17.7 (± 12.1) |
+5.3 (± 6.2) |
404 (± 20.0) |
+10.5 (± 4.9) |
+10.9 (± 5.8) |
-0.6 (± 15.0) |
-23.1 (± 6.6) |
| FEV1, mL |
2,567 (± 225) |
-134 (± 67.7) |
-130 (± 47.2) |
-23.8 (± 93.6) |
+78.8 (± 59.6) |
2,540 (± 179) |
+105 (± 72.5) |
-39.2 (± 74.7) |
+144 (± 106) |
-94.5 (± 48.0) |
| β2-agonist use per day |
3.9 (± 0.6) |
-0.8 (± 0.47) |
-1.2 (± 0.68) |
-0.3 (± 1.0) |
-0.4 (± 0.4) |
3.7 (± 0.5) |
-0.8 (± 0.25) |
-0.9 (± 0.32) |
-1.1 (± 0.4) |
+0.6 (± 0.47) |
| Severity score |
2.0 (± 0.02) |
-0.3 (± 0.1) |
-0.3 (± 0.1) |
-0.03 (± 0.04) |
-0.1 (± 0.1) |
1.8 (± 0.7) |
-0.3 (± 0.1) |
-0.3 (± 0.1) |
-0.4 (± 0.2) |
+0.1 (± 0.2) |
| **Total mornings |
5.7 (± 0.8) |
-1.8 (± 0.8) |
-3.2 (± 0.9) |
-2.3 (± 1.4) |
-0.8 (± 2.2) |
3.2 (± 0.6) |
-0.7 (± 0.4) |
-1.1 (± 0.7) |
-0.6 (± 0.5) |
+0.4 (± 0.3) |
| **Total awakenings |
1.5 (± 0.9) |
-0.8 (± 0.7) |
-0.8 (± 0.5) |
-1.1 (± 0.7) |
+0.4 (± 1.1) |
1.8 (± 0.7) |
-0.6 (± 0.5) |
-0.9 (± 0.6) |
-1.6 (± 0.7) |
+1.4 (± 1.0) |
|
|
||||||||||
|
Reid et al. Journal of Negative Results in BioMedicine 2008 7:3 doi:10.1186/1477-5751-7-3 |
||||||||||
